BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
BioCentury | Apr 2, 2015
Finance

Public Funding Notebook: Expanding access, limiting grants

Expanding access, limiting grants The push to expand access to funding for young and new investigators has led to new policies at two NIH agencies. In January, the National Institute of General Medical Sciences (NIGMS)...
BioCentury | Dec 23, 2013
Company News

Depomed, Nautilus Neurosciences sales and marketing update

Depomed gained U.S. rights to Cambia diclofenac oral solution for migraines from Nautilus. Nautilus will receive $48.7 million in cash up front and will be eligible for up to $5 million in milestones on net...
BioCentury | Dec 19, 2013
Company News

Depomed jumps on U.S. acquisition of migraine drug

Depomed Inc. (NASDAQ:DEPO) jumped $1.47 (18%) to $9.82 on Wednesday after announcing late Tuesday that it gained U.S. rights to migraine drug Cambia diclofenac oral solution from Nautilus Neurosciences Inc. (Bedminster, N.J.). Nautilus will receive...
BioCentury | Oct 15, 2012
Company News

Stellar Pharmaceuticals sales and marketing update

Stellar and its Tribute Pharmaceuticals operating division launched Cambia diclofenac oral solution in Canada to treat acute migraine headaches with or without aura in adults. The wholesale price for a nine-dose pack is C$89.10 ($91)....
BioCentury | Apr 2, 2012
Clinical News

Cambia diclofenac regulatory update

Health Canada approved Cambia diclofenac from Stellar's Tribute Pharmaceuticals subsidiary for the acute treatment of migraine attacks with or without aura in adults. The company plans to launch the product next half. FDA approved Cambia...
BioCentury | Feb 6, 2012
Finance

DBV readies IPO

French allergy play DBV Technologies is the second company this year to announce plans for an IPO on Euronext Paris. DBV has filed its "document de base," the French equivalent of a preliminary prospectus. Once...
BioCentury | Nov 22, 2010
Company News

Nautilus Neurosciences Inc., Tribute Pharmaceuticals sales and marketing update

Nautilus granted Tribute an exclusive license to develop and commercialize Cambia diclofenac powder in Canada. Tribute will be responsible for obtaining Canadian regulatory approval for the oral formulation of diclofenac potassium powder using Dynamic Buffering...
BioCentury | Oct 11, 2010
Company News

Mission Pharmacal, Nautilus Neurosciences sales and marketing update

The companies will co-promote Nautilus' oral Cambia diclofenac powder to treat migraine with or without aura in the U.S. to gynecologists, obstetricians and other women's health physicians. Nautilus said it is now looking for a...
BioCentury | Jun 14, 2010
Company News

Nautilus Neurosciences Inc., Kowa sales and marketing update

Nautilus launched oral Cambia diclofenac powder in the U.S. to treat acute migraine attacks with or without aura. The wholesale acquisition cost (WAC) of the product is $171.90 for a box of nine doses. Nautilus...
Items per page:
1 - 10 of 18